JP2016523245A - Ｄｅ−ｖｄｂｐ及び不飽和脂肪酸とのビタミンｄ複合体、並びに治療法におけるその使用 - Google Patents

Ｄｅ−ｖｄｂｐ及び不飽和脂肪酸とのビタミンｄ複合体、並びに治療法におけるその使用 Download PDF

Info

Publication number
JP2016523245A
JP2016523245A JP2016520738A JP2016520738A JP2016523245A JP 2016523245 A JP2016523245 A JP 2016523245A JP 2016520738 A JP2016520738 A JP 2016520738A JP 2016520738 A JP2016520738 A JP 2016520738A JP 2016523245 A JP2016523245 A JP 2016523245A
Authority
JP
Japan
Prior art keywords
vitamin
vdbp
vdr
complex
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016520738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523245A5 (enExample
Inventor
ルッギエロ、マルコ
Original Assignee
ノークス、デイビッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1311134.9A external-priority patent/GB2515347A/en
Priority claimed from GB201403508A external-priority patent/GB201403508D0/en
Application filed by ノークス、デイビッド filed Critical ノークス、デイビッド
Publication of JP2016523245A publication Critical patent/JP2016523245A/ja
Publication of JP2016523245A5 publication Critical patent/JP2016523245A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2016520738A 2013-06-21 2014-06-13 Ｄｅ−ｖｄｂｐ及び不飽和脂肪酸とのビタミンｄ複合体、並びに治療法におけるその使用 Pending JP2016523245A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1311134.9A GB2515347A (en) 2013-06-21 2013-06-21 Vitamin D-based complexes for use as supplements
GB1311134.9 2013-06-21
GB1403508.3 2014-02-27
GB201403508A GB201403508D0 (en) 2014-02-27 2014-02-27 Vitamin D-based complexes
PCT/GB2014/051824 WO2014202956A1 (en) 2013-06-21 2014-06-13 Vitamin d complexes with de-vdbp and an unsaturated fatty acid, and their use in therapy

Publications (2)

Publication Number Publication Date
JP2016523245A true JP2016523245A (ja) 2016-08-08
JP2016523245A5 JP2016523245A5 (enExample) 2017-03-09

Family

ID=51210682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016520738A Pending JP2016523245A (ja) 2013-06-21 2014-06-13 Ｄｅ−ｖｄｂｐ及び不飽和脂肪酸とのビタミンｄ複合体、並びに治療法におけるその使用

Country Status (5)

Country Link
US (1) US20160220587A1 (enExample)
EP (1) EP3010510A1 (enExample)
JP (1) JP2016523245A (enExample)
RU (1) RU2015156397A (enExample)
WO (1) WO2014202956A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
PH12018000227A1 (en) * 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
RU2759016C2 (ru) * 2018-02-07 2021-11-08 Общество с ограниченной ответственностью "ХЭТВУД" (ООО "ХЭТВУД") Теплоизоляционный материал на основе древесного волокна

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962523A (ja) * 1982-10-04 1984-04-10 Toyo Jozo Co Ltd 抗腫瘍剤
JP2003532682A (ja) * 2000-05-09 2003-11-05 チルドレンズ メディカル センター コーポレーション 血管新生の治療のための方法および組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012784A2 (en) * 2007-07-20 2009-01-29 Nya Hamlet Pharma Ab Methods for preparing cytotoxic complexes of emulsifier and fatty acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962523A (ja) * 1982-10-04 1984-04-10 Toyo Jozo Co Ltd 抗腫瘍剤
JP2003532682A (ja) * 2000-05-09 2003-11-05 チルドレンズ メディカル センター コーポレーション 血管新生の治療のための方法および組成物

Also Published As

Publication number Publication date
WO2014202956A1 (en) 2014-12-24
RU2015156397A (ru) 2017-07-26
EP3010510A1 (en) 2016-04-27
US20160220587A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
Song et al. Internalization of garlic-derived nanovesicles on liver cells is triggered by interaction with CD98
KR102090740B1 (ko) 암 치료 및 식품 관련 화합물을 포함하는 의학 분야에서 양친매성 또는 소수성 분자를 위한 나노입자, 제조 방법 및 담체로의 용도
US9907846B2 (en) Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
Chen et al. Cucumber-derived nanovesicles containing cucurbitacin B for non-small cell lung cancer therapy
Feng et al. Biomimetic grapefruit-derived extracellular vesicles for safe and targeted delivery of sodium thiosulfate against vascular calcification
Kuai et al. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
JPS6212724A (ja) ＩＦＮ−ｒ含有医薬組成物
AU711294B2 (en) Immunomodulating compositions from bile for the treatment of immune system disorders
EP0717631B1 (en) Immunomodulating compositions from bile
WO2019025922A1 (en) COMPOSITION FOR USE IN PREVENTING AND TREATING IRON DEFICIENCY
Luo et al. Selenopeptide nanomedicine ameliorates atherosclerosis by reducing monocyte adhesions and inflammations
JP2016523245A (ja) Ｄｅ−ｖｄｂｐ及び不飽和脂肪酸とのビタミンｄ複合体、並びに治療法におけるその使用
Wang et al. Programmed prodrug breaking the feedback regulation of P-selectin in plaque inflammation for atherosclerotic therapy
Zeng et al. Emerging trends in the application of extracellular vesicles as novel oral delivery vehicles for therapeutics in inflammatory diseases
JP2023533797A (ja) 脂質複合体を含む経口医薬組成物
TW200425900A (en) Pharmaceutical composition for enhancing immunity, and extract of poria
JPS6236331A (ja) 抗感染症剤ならびに免疫賦活剤
CN112423766A (zh) 含有A型CpG寡脱氧核糖核苷酸的脂质颗粒
TWI786706B (zh) 包含陽離子脂質體的組成物於抑制皂素溶血的用途
GB2515347A (en) Vitamin D-based complexes for use as supplements
KR102383031B1 (ko) 부갑상선 호르몬 약제의 경구전달용 나노 복합체
Sonkawade et al. Phospholipid encapsulation of an anti-fibrotic endopeptide to enhance cellular uptake and myocardial retention
US6551623B1 (en) Immunomodulating compositions from bile
TWI293956B (en) Disialoundecaglycosylasparagine - fatty acid amide and medicine containing the same
US20090081284A1 (en) Therapeutic agent for allergy containing liposome having oligosaccharide on its surface

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180612